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Summary
Each year over a million infants are born to HIV infected mothers though with scale up of
prevention of mother to child transmission (PMTCT) interventions, only 210,000 of the 1.3
million infants born to mothers with HIV/AIDS in 2012 became infected. Current programmatic
efforts directed at infants born to HIV-infected mothers are primarily focused on decreasing their
risk of infection, but this emphasis on maternal interventions has meant follow-up of exposed
infants has been poor. Programs are struggling to retain this population in care until the end of
exposure, typically at the cessation of breastfeeding, between 12 and 24 months of age. But HIV
exposure is a life-long condition that continues to impact the health and well-being of a child long
after exposure has ended. A better understanding of the impact of HIV on exposed infants is
needed and new programs and interventions must take into consideration the long-term health
needs of this growing population. The introduction of lifelong treatment for all HIV-infected
pregnant women is an opportunity to rethink how we provide services adapted for the long-term
retention of mother-infant pairs.
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Currently, over 1 million HIV exposed (HIV-E) infants are born to HIV-infected women
worldwide every year though the majority of these infants will not become infected. Most
are born in resource-limited settings and therefore exposed to increased mortality and
morbidity common for children in such regions. In addition, a limited but growing body of
evidence suggests that HIV exposure itself may contribute to poor health outcomes as well
as a host of unique psychosocial and economic challenges that can have a profound effect on
their overall well-being and ultimate outcomes. Access to health care, education, and social
services may also be affected due to family and social circumstances. Even when the risk of
HIV infection has passed, HIV-exposed uninfected (HIV-EU) infants will continue to be
affected by the impact of HIV on their families, to potential long-term adverse effects of
antiretroviral drugs, and to a higher risk for acquisition of HIV-related infections through
parental exposure during childhood.
The scale-up of prevention of mother-to-child transmission (PMTCT) programs has
significantly reduced perinatal HIV infection rates [1]. Programs which have been
successful include the implementation of effective provider initiated testing and counseling
(PITC) services, increased availability to antiretroviral prophylaxis and therapy (ART) for
pregnant women and their infants, improved delivery practices for HIV-infected women,
and an enhanced understanding of how to minimize risk of transmission during the
breastfeeding period. [2] Despite the increasing access to HIV-related services for women
during pregnancy, most need long-term service provision to ensure optimal outcomes.
Interestingly, implementing an agreed upon ‘package of services’ for these women and their
infants has been challenging and more efforts are needed to help countries define and
implement what these services should be and where and how these services should be
offered.
Although the numbers of new pediatric HIV infections will continue to decline as the
number of pregnant women and mothers having access to effective PMTCT interventions
increase, improving the delivery of services to HIV-exposed infants continues to be a
priority for both PMTCT and Pediatric HIV programs in most resource-limited settings.
Furthermore, as more adults benefit from ART and have healthier and longer lives the
population of HIV-E infants is likely to increase, highlighting the importance and need for
countries to strengthen the capacity to provide quality long-term services for this population.
These efforts should ideally be complementary to national and international efforts to
improve overall child survival as HIV-EU children are still at risk from preventable
childhood diseases such as measles, malnutrition, and tuberculosis (TB).
II. Long-Term Impact of HIV Exposure on Infant and Childhood Health
Outcomes
The prenatal period and the first few years of a child’s life set the stage for long-term
physical and mental health. While better understanding of the long-term impact that HIV has
on HIV-EU in resource-limited settings is needed, there is evidence that early exposure to
HIV has health effects lasting beyond the transmission period. [3] The effects of exposure to
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HIV itself must be considered as well as the impact of environmental factors related to birth
into a HIV-affected household including orphanhood, stigma, discrimination, and extreme
poverty. A brief review of these concerns is helpful as we rethink the types and duration of
services, interventions and surveillance needed to ensure optimal outcomes for these
children.
Evidence of Increased Morbidity and Mortality
Initial evaluation of increased morbidity and mortality in HIV-E infants in Africa arose from
early trials to evaluate PMTCT regimens. A pooled analysis of seven such trails found that
risk factors for death among HIV-E infants included maternal death, lower maternal CD4
counts [4], and early weaning [5] (See Infant Feeding paper in this series). Though maternal
ART adherence is effective in reducing under-5 mortality, [6] further studies continue to
link increased risk of child mortality with poor maternal health and HIV exposure and there
is a need to better understand what drives this increased risk of death to develop effective
prevention strategies. [7,8]
The reasons for increased morbidity and mortality are likely multifactorial, but there is some
evidence that HIV exposure in utero or during the postnatal period affects development of
the infant’s immune and other organ systems. Moreover, HIV exposure and maternal
placental responses to the virus have resulted in modifications or interference with the
immune response of HIV-EU infants, resulting in immunological abnormalities and
increased susceptibility to childhood diseases. [7,9]
The immune system is underdeveloped at birth and as a result infants and young children
may be thought of as immune-compromised regardless of previous HIV-exposure.[10] HIV-
infected women or HIV-infected family members are at high risk for co-infection with
opportunistic pathogens and are more likely to transmit horizontally to children, resulting in
an increased risk of primary acquisition of HIV-related infections in children.[11,12] In
addition, HIV-E infants are more susceptible to congenital or acquired infections with TB ,
herpes and cytomegalovirus (CMV) than their unexposed peers. Globally, CMV is the most
commonly transmitted infection from mother to child, occurring in 0.2 percent–2.2 percent
of live-born infants in the United States with similar transmission rates likely in resource
limited settings. The prevalence of CMV infection among HIV-infected pregnant women is
higher than in the general population, with approximately 90% of HIV-infected pregnant
women co-infected with CMV [13].
Cotrimoxazole prophylactic treatment (CPT) is currently recommended for all HIV-E
infants and while the benefits are clear for HIV infected children the evidence of benefit for
uninfected infants is less so.[14,15] The Breastfeeding, Antiretrovirals, and Nutrition (BAN)
study demonstrated that the use of prophylactic cotrimoxazole was associated with reduced
rates of morbidity and mortality in HIV-EU infants. However, other than temporary
protection from malaria, CPT offered no protection against anemia, malnutrition or severe
illness and death for HIV negative children.[16,17] Given limited data that CPT may
increase risk of diarrheal illness in HIV uninfected infants there is a need to define the
optimal duration of cotrimoxazole prophylaxis and possibly reexamine current guidelines.
[18]
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Growth stunting is associated with preterm or low birth weight infants both of which occur
more commonly in infants born to HIV-infected mothers. [19,20] Additionally, growth
stunting is associated with discontinuation or reduction in breastfeeding which significantly
effects a child’s health and cognitive development. [20,21] Differences in growth between
HIV-EU and unexposed children typically present in the first months of life and some
studies on postnatal growth show minimal difference in early growth of HIV-EU children
compared to unexposed controls.[22]
With the rollout of Option B+ (provision of lifelong triple drug therapy for HIV-infected
pregnant women not dependent on CD4 count), the impact of exposure to triple therapy on a
child’s growth and development needs to be closely examined. Recent evidence from the
Mashi and Mma Bana trials in Botswana revealed that both weight for age and length for
age were significantly lower in HIV-E infants exposed to ART in utero compared to those
that were only exposed to maternal single drug prophylaxis with AZT. [23] It remains
unclear whether these differences have a short term impact or whether they predispose the
child for subsequent poorer health, obesity, chronic disease or cognitive dysfunction.[24]
The impact of prenatal ARV exposure on neurocognitive development given the association
of nucleoside reverse transcriptase inhibitors (NRTI’s) with mitochondrial toxicity is also of
concern.[25,26] Early reports of birth defects and mitochondrial toxicity from exposure to
ARVs remains equivocal and while a French study reported 0.5% of ARV exposed children
had mitochondrial dysfunction [27] more recent evidence evaluating outcomes in HIV-EU
children found no association between in utero exposure to any ARV and
neurodevelopmental outcomes when assessed using a standardized measure of infant
development. [28, 29] Similarly evidence suggests that most detectable developmental
delays among HIV-EU children are a result of environment factors and not a consequence of
in-utero or postnatal HIV exposure and that with improved attention to a child’s early
developmental and psychosocial needs such delays may be prevented or reversed.[27-30]
Potential for short and long-term antiretroviral -related toxicity
At present the benefits of ART reducing vertical transmission and improving maternal
health greatly outweigh the potential adverse effects of ART exposure to children. However
as PMTCT coverage increases the number of uninfected infants exposed to antiretroviral
therapy (ARV) in utero or through breastfeeding will likewise increase making it critical to
continue to monitor for adverse effects. Considerable data link protease inhibitors to preterm
delivery and low birth-weight.[31-33]. Hematologic abnormalities may also be associated
with exposure to ARV’s; both short and long term effects on several hematologic parameters
have been noted in infants exposed in utero and post-natally to different ARV’s.[34] Firm
conclusions about the potential long-term physiologic effects of exposure to ARVs in utero
are lacking as significant heterogeneity often exists between studies, however the benefits of
antenatal exposure to ARV’s must be weighed against an understanding of any risk. Of
greatest importance is ensuring the most effective and acceptable regimens are available, as
the risks of virologic non-suppression are substantial for both the woman and the child.
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As more pregnant women living with HIV initiate ART during pregnancy, many women are
likely to become pregnant again while taking the preferred first line regimen containing both
tenofovir (TDF) and efavirenz (EFV). There has been concern about the use of EFV in
pregnancy due to the association with heterogeneous central nervous system defects in
animal studies. However a recent meta-analysis reported only one neural tube defect in
infants born to women on EFV-based as compared to non-EFV-based regimens; a lower rate
than what is reported for the general population.[35] Therefore, while it appears that the
potential risks to the infant with EFV exposure is very low, definitive studies and birth
defect surveillance with larger sample sizes are needed (and are ongoing), there is not reason
to limit use of EFV in pregnant women. [36, 37]
Tenofovir (TDF) is known to affect bone mineral density and renal function in adults,
although the clinical significance of these effects is still not clear.[38-40] Infants exposed to
TDF in-utero have been found to demonstrate no growth parameter (e.g., birth weight,
length) differences when compared with infants exposed to non-TDF containing regimens.
[41] The US Pediatric HIV/AIDS Cohort Study compared infants exposed to combination
drug regimens in-utero with and without TDF and found no differences at birth between the
two groups (e.g., birth weight, length, or head circumference). However, at one year of age,
those infants who were exposed to TDF in-utero were found to have a small but statistically
significant difference in length-for-age and head circumference-for-age compared with
TDF-unexposed infants. [42] While current literature does not show any serious risks
associated with TDF exposure in utero, the evidence is limited and does suggest more
research is warranted. The US Antiretroviral Pregnancy Register has seen a rate of all birth
defects in infants exposed to TDF in the first trimester of 2.3%, equivalent to the 2.7%
prevalence seen in the overall US population. [43]
Impact of living in households affected by HIV
A growing body of evidence indicates that an adverse intra-uterine environment and
maternal stressors during early infancy significantly affects a child’s long-term
development. [44] In addition, HIV affected households may experience various economic
and psychosocial stressors that in turn can increase a child’s vulnerability.
Limited data that exists examining the psychosocial development and experiences of HIV-
EU children making it difficult to isolate the stressors and risk factors associated with HIV
exposure. Some studies have demonstrated that maternal stressors associated with the onset
of HIV symptoms can affect a child’s psychosocial adjustment [45,46] while other studies
indicated that it is a mother’s illness or physical well being, not maternal HIV status that
affects a child’s behavior (See Psychosocial paper in this series). [46] Of particular interest,
is the relationship between a parent’s disclosure of their illness or HIV status and an HIV-E
infant’s access to healthcare services, psychosocial adjustment and resilience.[46,47] Non-
disclosure of a parent’s HIV status is associated with increased levels of depression and
anxiety among HIV affected children.[48,49]
By virtue of living in an HIV affected household, HIV-E children are often exposed to
death, illness and family disruptions at an early age. If there are other children or adults
living with HIV in the household the needs o HIV-EU children may not be prioritized, as
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food and healthcare may be rationed to care for ill family members. [48] Illness within the
family can result in income loss, decreased food availability, frequent relocation and lower
rates of school attendance.[50] A study conducted in South Africa to identify the reasons for
loss to follow up among HIV-E children underscored the role that poverty and socio-
economic conditions played on members of an HIV affected household’s long-term access
to healthcare.[51] Due to changes in family composition and orphan hood, HIV-E children
may also have multiple caregivers or live outside their home of origin and may be treated
differently from non -HIV- affected relatives.[50]
In 2011, an estimated 15.2 million children in sub-Saharan Africa were orphaned due to
AIDS and it is likely that a significant proportion of these orphans were also HIV-E. [1,52]
While more nuanced data on orphan hood and HIV exposure is needed, findings from the
literature on the impact of orphan hood on the psychosocial development of children may
provide additional clues regarding the stressors experienced by HIV exposed children. Two
studies on the relationship between stigma and psychosocial well-being in South Africa and
China showed that AIDS orphans reported higher levels of stigma, which was associated
with poorer psychological outcomes.[53,54] In South Africa, AIDS orphans engaged in less
positive activities and were more likely to experience higher rates of depression, post-
traumatic stress, delinquency and difficulties with peer relationships compared to children
orphaned by other causes.[55] Similarly, children orphaned by AIDS are less likely to
receive social or economic support and therefore do not reap the documented psychological
benefits of such assistance; namely lower rates of depression, anxiety, bullying, and
behavioral problems.[56]
Resiliency in HIV-affected Children
Resiliency, or the ability to overcome stressors in a psychologically healthy way, amongst
AIDS orphans is attributed to caregiver quality, contact with immediate and extended family
and school attendance; while risk factors for poor outcomes include bereavement, frequent
changes in caregivers, caregiver illness, discrimination as a result of living in another
household and exposure to abuse or violence.[56] Studies have shown that male
involvement and a mother’s status as a member of an association of people living with HIV
(PLHIV) can have a positive influence on an infant’s health outcomes.[57] These findings
highlight the importance of ensuring that HIV-E infants and their families are appropriately
evaluated and referred to programs in the community, including those that are aimed at
providing support for Orphans and Vulnerable Children(OVC).
III. Programmatic Challenges and Opportunities
Guidance for the care of HIV-E infants has largely centered on recommendations to
minimize the risk of transmission through delivery of appropriate antenatal care (ANC)
services, encouragement of safe delivery practices, use of ARV prophylaxis and promotion
of optimal feeding during breastfeeding (Table 1). The greatest challenge with providing
services for these children is addressing some of the issues that affect retention in care
through the end of the exposure period. However longer follow-up should be encouraged to
address the health impacts of exposure and provide needed support to alleviate or prevent
negative outcomes that may manifest after the risk of HIV transmission has passed.
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Factors that affect retention of these infants in care are multiple and include those stemming
from the health care system itself particularly staffing and infrastructure, as well as social
and individual or family factors. There has been limited success in conducting routine and
systematic monitoring of HIV-E infants towards the end of breastfeeding. This is illustrated
by the lack of data available on the proportion of HIV-E infants with confirmed HIV status
at 18 months of age.[1] Quality of early infant diagnosis services and long turnaround times
for results may also affect levels of trust in the health care system and influence adherence
to follow up care and the use of prophylactic medications [58]
An additional programmatic challenge has been the lack of standardized, easy to use tools
for mother-infant pair tracking and site-level and program data collection. Most services for
HIV-E and infected infants currently take place within PMTCT program settings, though
increasingly the introduction of lifelong treatment for HIV-infected pregnant women and the
emphasis on decentralization of care means that more mothers and families could be
receiving care in health center settings.
Full integration of HIV services for women and their infants into health centers would
require modification of registers used during pregnancy, in delivery units and in postnatal
care sites to link women to their infants from the time of ANC diagnosis through 24 months
of age or beyond. In addition, the lack of simple medical records for HIV-E infants adds
additional challenges faced by health care providers and programs. Some countries have
added information related to maternal HIV and HIV-E infant interventions to the hand-held
cards that women carry during pregnancy and in under-5 childhood health cards in order to
facilitate the identification of exposed infants each time they access the health care system.
This allows health care providers to tailor services to address specific needs for mother-
infant pairs at each health encounter.
Maternal health is critical to child survival and long-term development, yet care is often
provided to mother-infants pairs separately. Currently there is vague guidance on the best
service delivery model for HIV-E infants. PMTCT programs generally focus on maternal
interventions while pediatric care and treatment programs are designed to care for HIV
infected children. While provision of early infant diagnosis in MCH platforms is effective in
some settings, longer term care to improve retention and HIV free survival will require a
shift in the organization of programs which have historically been vertically implemented in
most countries.[59]
Providing specialized follow up care for at risk children, separate from well-child clinics
may contribute to stigma and discourage mothers from accessing services. Fear of disclosure
may also inhibit caregivers from getting children tested, or even initiating treatment, making
identification and follow up of HIV- E and -infected children more challenging. [60]
Treatment initiation, as with most child health issues is a family decision; limited male
involvement may also be a barrier to providing more comprehensive care to HIV-E infants
in order to prevent transmission, ensure HIV-free survival and provide care for optimal
development beyond the confirmation of final HIV status.
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As many countries are shifting their PMTCT programs towards the use of antiretroviral
therapy throughout the duration of pregnancy and breastfeeding, if not for life, there is a
need to adapt service delivery models to ensure the long-term retention of women on
treatment. This need offers a great opportunity for improving how programs follow and
offer services to the infants born to HIV infected women. Ideally, services and interventions
for mother-infant pairs should be provided at the same time and preferably in the same
setting. Some of these interventions include screening for TB in the child and family
members, supporting cotrimoxazole adherence, ensuring all childhood vaccines are
provided, and assessing family support needs and establishing linkages with OVC programs
to minimize negative psychosocial, developmental and financial effects.
IV. Research Gaps
As PMTCT programming becomes more refined and effective, the number of HIV-EU
infants will continue to grow. Gaining a deeper and more nuanced understanding of the
impact HIV and ARV exposure in-utero and in infancy has on children’s physical and
psychological development is crucial to providing better care. ARV toxicity surveillance for
pregnant and breastfeeding women and their infants and more robust systems to capture
pregnancy outcomes, such as birth defect surveillance or following long-term cohorts of
HIV-EU children are a priority to more fully understand the effects of ARVs on this
population. This is particularly critical in resource-limited settings where malnutrition and
comorbidities are more common and where monitoring capacity is limited. Linked to
toxicity monitoring is the potential/need to further investigate the efficacy, safety and
viability of alternative ARVs for prophylaxis, particularly as resistance to nevirapine and
potentially zidovudine are concerns for children who become infected. Further investigation
is needed to understand the the immune-response of HIV-EU infants to determine whether
HIV or ARV exposure compromises the ability to ward off future infections and if the
benefits of cotrimoxazole prophylaxis outweighs the risks for HIV-EU infants.
Emerging evidence demonstrates that early stress and shocks in utero and for the first two
years of life have significant impact on a child’s development into adulthood though very
few studies have begun to isolate the medium and long-term psychosocial impacts of HIV
exposure compared with HIV-infected and non-affected children. More research to explore
the interplay between neurological insults and cognitive and psychosocial development is an
area that deserves more attention.
Operations research to evaluate the effectiveness of specific programmatic interventions
such as integrated follow up of HIV-E infants with growth monitoring, immunization and
other well child services should be considered as postpartum follow up of mother infant
pairs is weak in most programs. While there is some evidence that these programming shifts
have increased rates of EID testing and treatment initiation among infants and young
children, determining which interventions individually and in combination have the greatest
impact on improving HEI identification and follow up is an area for further research.[61]
Considering that post-partum and post-natal care is weak in many programs, identifying the
determinants of post natal care uptake –both structural and socio-cultural may provide key
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insights into the barriers that impede mothers from accessing post-partum care, which in
turn, may point to potential solutions for reducing loss to follow up among HEI.
V. Conclusion/Recommendations
Until recently, the long-term effects of HIV and ARV exposure on uninfected infants and
children has received limited attention. Yet, the number of HIV-EU children will expand in
the coming years assuming that MTCT rates continue to decline. While pediatric HIV can be
considered a neglected disease, the care of HIV-E and HIV-EU infants and children is even
more overlooked. Retention and provision of follow-up care to mother-infant pairs through
the end of exposure to minimize risks of HIV transmission is critical, as is reinforcing
provider initiated testing and counseling at all entry points and training health staff on
specific needs of HIV-E during and beyond risk of transmission is also important.
The evidence suggests that the effects of HIV ad ARV exposure extend through childhood
and beyond. Providing comprehensive care for HIV-E, HIV infected and HIV-EU children
requires a paradigm shift and significant changes to programmatic approaches. Community
outreach to highly vulnerable children for active case finding and referral to support
services, such as food assistance, cash transfers, and social welfare should be integral to all
programs. Strengthening linkages with community-based testing and support services and
OVC programs is imperative to increase identification of HIV exposed and infected children
and to provide longer term care and support through home visits to all children who are ill.
Essentially, these recommendations call for a shift away from individual disease specific
care to family-friendly services that address the spectrum of health needs along different
time points, promote safe disclosure and adherence support. Strengthening family and
community involvement from ANC, throughout pregnancy and infancy may reduce stigma
and discrimination and help to overcome persistent barriers to identifying and caring for
these infants.
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Table 1










• Maternal screening for HIV infection at first antenatal visit
• Maternal triple ARV prophylaxis for all HIV-infected pregnant women using preferred
1st line adult regimen: TDF+3TC (or FTC)+ EFV





• Continued maternal support to ensure adherence to ART or HIV specific prophylaxis
• HIV testing of women of unknown status presenting at the time of delivery or repeat
testing for previously negative pregnant women
• Encourage facility-based delivery
• Avoidance of unnecessary instrumentation and premature ROM
• Non-invasive suctioning of nasogastric secretions in the newborn





• Continued maternal ART to prevent breastfeeding transmission and to preserve maternal
health.
• Infant HIV prophylaxis to be initiated at birth or when HIV exposure is recognized
postpartum
• For breastfeeding infants, daily NVP for a minimum of 6 weeks should be initiated
shortly after birth. Prophylaxis may be extended to 12 weeks in case of late maternal
presentation or suboptimal viral suppression; may be restarted if mother interrupts ART
during breastfeeding
• Infants receiving exclusive replacement feeds 4-6 weeks of daily NVP or twice daily
AZT
• If infant NVP is not available, 3TC may be substituted
Cotrimoxazole
Prophylaxis
4-6 weeks of age
(infants)
• Initiation of cotrimoxazole prophylaxis with continued administration until/if HIV
infection is excluded
HIV Testing
4-6 weeks of age
(infants)
• Virologic HIV testing for infants with known HIV exposure
• Serologic testing for mothers of infants with unknown HIV exposure
9 months of age
(infants)
• Serologic testing at time of last immunization (measles immunization) followed by
virological testing if serology is reactive
Symptomatic
infant at any age
• Serologic testing for any infant with signs and symptoms suggestive of HIV infection
followed by virological testing if serology reactive (presumptive treatment may be





• Serologic testing at least 6 weeks after the end of breastfeeding followed by virological
testing for infants with reactive HIV serology
Infant
Feeding/Nutrition
Birth - 6 months
• Exclusive breastfeeding for first six months of life with strict avoidance of mixed
feeding should be encouraged
• Exclusive replacement feeding if AFASS criteria can be met if mother not breastfeeding
6- 12 months of
age
• Introduction of complementary foods at 6 months and continued breastfeeding




































• Safe water interventions
• Maternal malaria prophylaxis
• Insecticide treated bed nets
• Growth monitoring and routine childhood immunizations
*
Some services may need to be extended beyond 24 months, depending on the duration of breastfeeding and other factors.
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